Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma

Mari Kogiso,Lin Qi,Yuchen Du,Frank K. Braun,Huiyuan Zhang,L. Frank Huang,Lei Guo,Yulun Huang,Wan-Yee Teo,Holly Lindsay,Sibo Zhao,Sarah G. Injac,Zhen Liu,Vidya Mehta,Diep Tran,Feng Li,Patricia A. Baxter,Jack M. Su,Laszlo Perlaky,D. Williams Parsons,Murali Chintagumpala,Adekunle Adesina,Yongcheng Song,Xiao-Nan Li
DOI: https://doi.org/10.1016/j.tranon.2022.101368
IF: 4.803
2022-04-01
Translational Oncology
Abstract:Clinical outcomes in patients with WHO grade II/III astrocytoma, oligodendroglioma or secondary glioblastoma remain poor. Isocitrate dehydrogenase 1 (IDH1) is mutated in > 70% of these tumors, making it an attractive therapeutic target. To determine the efficacy of our newly developed mutant IDH1 inhibitor, SYC-435 (1-hydroxypyridin-2-one), we treated orthotopic glioma xenograft model (IC-BT142AOA) carrying R132H mutation and our newly established orthotopic patient-derived xenograft (PDX) model of recurrent anaplastic oligoastrocytoma (IC-V0914AOA) bearing R132C mutation. In addition to suppressing IDH1 mutant cell proliferation in vitro, SYC-435 (15 mg/kg, daily x 28 days) synergistically prolonged animal survival times with standard therapies (Temozolomide + fractionated radiation) mediated by reduction of H3K4/H3K9 methylation and expression of mitochondrial DNA (mtDNA)-encoded molecules. Furthermore, RNA-seq of the remnant tumors identified genes (MYO1F, CTC1 and BCL9) and pathways (base excision repair, TCA cycle II, sirtuin signaling, protein kinase A, eukaryotic initiation factor 2 and α-adrenergic signaling) as mediators of therapy resistance. Our data demonstrated the efficacy SYC-435 in targeting IDH1 mutant gliomas when combined with standard therapy and identified a novel set of genes that should be prioritized for future studies to overcome SYC-435 resistance.
oncology
What problem does this paper attempt to address?